C3 Cannabinoid Compound
About C3 Cannabinoid Compound
C3 Cannabinoid Compound is a Healthcare company based in Germany, and was acquired by Dermapharm in December 2021. Cannabis-derived pharmaceutical products are manufactured, researched, and distributed. Its chief executive, as recorded, is Hans-Georg Feldmeier. The company was acqui-hired. Its focus areas include HealthTech, Cannabis HealthTech, Cannabinoid Therapeutics and Diversified.
Company details
Operations of C3 Cannabinoid Compound are centered in Germany within the pharmaceutical sector, where cannabis-derived products are manufactured and distributed. Research and development are conducted on therapeutic cannabinoids including tetrahydrocannabinol and cannabidiol. The initial offering, Dronabinol, is provided for managing nausea, vomiting, cancer-related symptoms, and palliative care needs. Leadership is provided by CEO Hans-Georg Feldmeier.
- Headquarters Germany
- Stage Acquired
- SectorsHealthcare
- Website c3-company.de
- Acquired by Dermapharm (Dec 2021)
- InvestorsCanopy Growth
& 1 more
- Acquired by
Investors in C3 Cannabinoid Compound
C3 Cannabinoid Compound has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Canopy Growth and Dermapharm.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Dermatological and pharmaceutical medications are developed and manufactured. | 1991 | dermapharm.de | Grunwald, Germany | |
Cannabis products are provided to support consumer wellness and health. | 2013 | canopygrowth.com | Smiths Falls, Canada |
Investor details for C3 Cannabinoid Compound
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of C3 Cannabinoid Compound
1 people are tracked at C3 Cannabinoid Compound (1 in leadership).
| Name | Role | Group |
|---|---|---|
Hans-Georg Feldmeier | CEO | Leadership |
Complete people profiles for C3 Cannabinoid Compound
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of C3 Cannabinoid Compound
2 dated milestones of C3 Cannabinoid Compound across 2 years, from founding to its latest funding, stage changes and deals.
- Exit Acquired by Canopy Growth.
- Exit Acquired by Dermapharm.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about C3 Cannabinoid Compound
C3 Cannabinoid Compound is headquartered in Germany.
Hans-Georg Feldmeier is the CEO of C3 Cannabinoid Compound, as recorded in our data.
Operations of C3 Cannabinoid Compound are centered in Germany within the pharmaceutical sector, where cannabis-derived products are manufactured and distributed. Research and development are conducted on therapeutic cannabinoids including tetrahydrocannabinol and cannabidiol. The initial offering, Dronabinol, is provided for managing nausea, vomiting, cancer-related symptoms, and palliative care needs. Leadership is provided by CEO Hans-Georg Feldmeier.
C3 Cannabinoid Compound has 2 investors. Key investors include Canopy Growth, and Dermapharm.
Yes. C3 Cannabinoid Compound was acquired by Dermapharm in December 2021.